General Information of the Drug (ID: M6APDG04091)
Name
OT-58
Status
Phase 1/2
TTD Drug ID
D87TMY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Serine sulfhydrase (CBS)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary Serine sulfhydrase (CBS) is a therapeutic target for OT-58. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OT-58 through regulating the expression of Serine sulfhydrase (CBS). [1], [2]
References
Ref 1 Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer. J Adv Res. 2021 Oct 5;37:91-106. doi: 10.1016/j.jare.2021.10.001. eCollection 2022 Mar.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)